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Abstract
Nanoparticles are poised to have a tremendous impact on the treatment of many diseases, but their
broad application is limited because currently they can only be administered by parenteral
methods. Oral administration of nanoparticles is preferred but remains a challenge because
transport across the intestinal epithelium is limited. Here, we show that nanoparticles targeted to
the neonatal Fc receptor (FcRn), which is known to mediate the transport of IgG antibodies across
epithelial barriers, are efficiently transported across the intestinal epithelium using both in vitro
and in vivo models. In mice, orally administered FcRn-targeted nanoparticles crossed the intestinal
epithelium and reached systemic circulation with a mean absorption efficiency of 13.7%*h
compared with only 1.2%*h for non-targeted nanoparticles. In addition, targeted nanoparticles
containing insulin as a model nanoparticle-based therapy for diabetes were orally administered at a
clinically relevant insulin dose of 1.1 U/kg and elicited a prolonged hypoglycemic response in
wild-type mice. This effect was abolished in FcRn knockout mice, indicating the enhanced
nanoparticle transport was due specifically to FcRn. FcRn-targeted nanoparticles may have a
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major impact on the treatment of many diseases by enabling drugs currently limited by low
bioavailability to be efficiently delivered though oral administration.
Introduction
Nanoparticles (NPs) have the potential to make a significant impact on the treatment of
many diseases, including cancer, cardiovascular disease, and diabetes. Many NP-based
therapeutics are now entering clinical trials or have been approved for use (1, 2), including
targeted polymeric nanoparticles ((3), clinical trial NCT01478893) based on technologies
that we have previously described (4). However, the impact of NPs in the clinic may be
limited to a narrow set of indications because NP administration is currently restricted to
parenteral methods. Many diseases that could benefit from NP-based therapeutics require
frequent administration. Alternate routes of administration, particularly oral, are preferred
because of the convenience and compliance by patients (5). Intestinal absorption of NPs is
highly inefficient because the physicochemical parameters of NPs prevent their transport
across cellular barriers such as the intestinal epithelium (6). To improve the absorption
efficiency of NPs and to make the oral administration of NPs practical in the clinic, new
strategies are necessary to overcome the intestinal epithelial barrier.
The neonatal Fc receptor (FcRn) mediates IgG transport across polarized epithelial barriers
(7, 8). It was discovered as the receptor in the neonatal intestine that transports IgG in breast
milk from mother to offspring (9). However, FcRn is expressed into adulthood at levels
similar to fetal expression in the apical region of epithelial cells in the small intestine and
diffusely throughout the colon (10). FcRn is also expressed in the vascular endothelium,
blood-brain barrier, kidneys, liver, lungs, and throughout the hematopoietic system (11, 12).
FcRn interacts with the Fc portion of IgG in a pH-dependent manner, binding with high
affinity in acidic (pH <6.5) but not physiological environments (pH ~7.4) (13). The
intracellular trafficking of the IgG:FcRn complex has been conclusively demonstrated in the
rat intestine using IgG Fc labeled with 1.4-nm gold as a contrast agent for electron
tomography (14). The studies revealed that Fc is transported through a complex pathway
involving a network of entangled tubular and irregular vesicles in order to reach the
basolateral surface of the cell.
We hypothesized that targeting NPs to FcRn using IgG Fc fragments would allow orally
administered NPs to be transported across the intestinal epithelium in rodents (Fig. 1). In
acidic sections of the intestine, such as the duodenum and portions of the jejunum (15), Fc
fragments conjugated to NPs [Fc-targeted NPs (NP-Fc)] will bind to FcRn at the apical
surface of absorptive epithelial cells, leading to receptor-mediated endocytosis (16). NP-Fc
could also be taken up by fluid phase pinocytosis. During intracellular trafficking, NP-Fc
and FcRn in the same acidic endosome compartments will bind with high affinity. FcRn can
then guide bound NP-Fc through a transcytosis pathway, avoiding lysosomal degradation
(17). On the basolateral side, exocytosis results in exposure to a neutral pH environment in
the lamina propria, causing the release of NP-Fc (18). NP-Fc can then diffuse through the
lamina propria and enter systemic circulation.
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Fc-fusion proteins have been used to overcome biological barriers: Fc fused with
erythropoietin was measured in non-human primates (19) and humans (20) after pulmonary
administration, indicating that using the FcRn is a valid transport pathway in humans; and
follicle-stimulating hormone fused with Fc reached circulation after oral delivery in
newborn rats (21). However, NPs offer several potential advantages over fusion proteins
including (i) transport of many drug molecules with each transcytosis event; (ii) protection
of drug molecules, particularly protein therapeutics, through encapsulation; and (iii)
mitigation of the need for drug modification. Recently, 20–50-nm fluorescent NPs
conjugated to IgG Fc were transported across an in vitro airway epithelial cell monolayer
(22). Yet no studies, to our knowledge, have used drug-encapsulated NPs to target the
FcRnfor oral drug delivery applications.
Herein, we developed polymeric NPs surface-modified with Fc to target FcRn, resulting in
transepithelial transport both in vitro and in vivo. NP-Fc demonstrated enhanced transport
specifically mediated by FcRn across an intestinal epithelial monolayer in vitro. In mice,
NP-Fc were imaged crossing the intestinal epithelium and entering the lamina propria after
oral administration. NP-Fc were also measured in several organs after oral administration,
indicating that NP-Fc were able to reach systemic circulation. Finally, NP-Fc encapsulating
insulin as a model NP-based therapeutic for diabetes were administered orally and elicited a
hypoglycemic response. These results demonstrate that NPs targeted to the FcRn are capable
of crossing an epithelial barrier in vivo using a transcytosis pathway.
Results
Preparation of Fc-Targeted Nanoparticles
NPs were formed from biodegradable and biocompatible poly(lactic acid)–b-poly(ethylene
glycol) (PLA-PEG) block copolymers. PLA is a biodegradable polymer used in many FDA-
approved products and forms the NP core owing to its hydrophobicity. PEG is a
biocompatible polymer that remains on the NP surface owing to its hydrophilic nature and
forms the NP corona. PLA-PEG was synthesized using ring-opening polymerization with a
free terminal maleimide group (PLA-PEG-MAL) to conjugate the Fc portion of IgG.
Studies of NPs have shown enhanced intestinal uptake as particle size decreases (23, 24).
However, these previous studies on particle size have mostly focused on nonspecific uptake
by M cells in the Peyer’s patches as opposed to specifically targeting the NPs to a
transcytosis pathway such as the FcRn-mediated pathway. Here, the nanoprecipitation self-
assembly method (25)(Fig. 2A) was used to generate particles with a mean hydrodynamic
diameter of 55 nm and a polydispersity of 0.05 (Fig. 2B).
Polyclonal IgG Fc fragments were covalently conjugated to PEG using maleimide-thiol
chemistry. 2-Iminothiolane was used to modify the Fc with thiol groups (Fc-SH). Fc-SH was
incubated with NPs for conjugation (Fig. 2A). The amount of Fc conjugated to the NPs was
measured for both Fc-SH and unmodified Fc (Fig. 2C). Unmodified Fc resulted in a lower
ligand density than Fc-SH, indicating minimal nonspecific interactions between Fc and the
NP surface and that the unbound Fc was successfully separated from NP using centrifugal
filtration. The ligand density for Fc-SH was 32-fold higher than unmodified Fc, indicating
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that Fc was bound on the NP surface. In addition, the hydrodynamic diameter of the NP
increased from 55 to 63 nm after Fc conjugation (Fig. 2B) - an increase consistent with the
hydrodynamic diameter of IgG Fc (~3 nm) (26). The surface charge showed only a minor
change from −4.3 ± 0.4 for NP to −5.6 ± 1.1 mV for NP-Fc (mean ± SD, n=3, p>0.05,
Student’s t test).
In vitro Transepithelial Transport
In vitro NP transepithelial transport studies were conducted using an epithelial cell
monolayer model with Caco-2 cells, a human epithelial colorectal adenocarcinoma cell line
typically used as a model of the intestine for drug permeability testing. Caco-2 cells
endogenously express human FcRn and human beta-2-microglobulin, and have previously
been used for IgG transcytosis studies (8, 27). 3H-labeled NPs were used to measure
transport across the Caco-2 monolayer. Using this system with a pH gradient established
from the apical to basolateral side of the Caco-2 polarized monolayer (to mimic the
physiological pH of the duodenum and enhance apical binding), the transcytosis of non-
targeted NPs (control) and NP-Fc was measured. 3H measurements for NP-Fc on the
basolateral side were twofold greater than non-targeted NPs after 24 h, indicating that Fc on
the NP surface significantly enhanced transepithelial transport in vitro (Fig. 2D). When NP-
Fc was combined with a 50-fold excess of free IgG Fc as a blocking agent for the FcRn
transcytosis pathway, NP-Fc transport was significantly reduced, indicating that the
enhanced transport of NP-Fc is at least partially receptor-mediated (Fig. 2D).
FcRn Expression in Mice
FcRn expression throughout the entire small and large intestine of wild-type mice was
confirmed by Western blot (Fig. 3A). Quantification of band intensity showed that the FcRn
expression decreased in the distal sections of the small intestine and the colon (Fig 3B).
Immunohistochemistry showed that FcRn was localized to the epithelium of the intestinal
villi of the duodenum of wild -type mice (Fig 3C).
In vivo Absorption and Biodistribution
In vivo transport of NP-Fc across the intestinal epithelium was visualized using fluorescently
labeled NPs. Fasted wild-type mice were orally administered the fluorescently labeled NPs,
and sections of the duodenum were collected and analyzed using confocal fluorescence
microscopy. Figure 3D shows representative images for both non-targeted NPs and NP-Fc.
For the non-targeted NPs, the fluorescence from the NPs was not observed in the villi,
suggesting that the NPs were unable to enter the villi. However, for the NP-Fc, fluorescence
was observed inside the villi on the basolateral side of the epithelial cells, indicating that
NP-Fc crossed the intestinal epithelium and entered the lamina propria(Fig. 3 D).
The biodistribution and absorption efficiency of both targeted and non-targeted NPs were
quantitatively measured by radiolabeling the NPs with 14C. Figure 4A shows the
biodistribution of non-targeted NPs and NP-Fc over the course of 8 hours after oral
administration to fasted wild-type mice. For the non-targeted NPs, a small amount of 14C
was measured in the organs. By contrast, a large amount of 14C was measured in the spleen,
kidneys, liver, and lungs for NP-Fc, indicating that NP-Fc entered systemic circulation after
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oral administration and reached several organs known to express FcRn (11). The 14C in the
organs was transient, peaking at 2.5 h post-delivery and clearing from the organs at later
time points (Fig. 4A). To ensure that the 14C remained with the NPs over the course of the
experiment, the release of 14C from the NPs was measured and no release was observed over
24 h (Fig. 4B).
The total 14C absorbed over time was calculated by summing the 14C measured in each of
the organs (spleen, kidneys, liver, heart, and lungs) at a specific time point (Fig. 4C).
Significantly higher amounts of 14C were absorbed for NP-Fc at 1.5, 2.5, and 4 h compared
with non-targeted NPs, indicating that Fc targeting enhanced absorption. The area under the
curve (AUC) was used to calculate the oral absorption efficiency, which was 1.2%*h ± 0.2
for non-targeted NPs and 13.7%*h ± 1.3 for NP-Fc (mean ± SEM with n=5 mice per
timepoint; P < 0.001, Student’s t test). This difference in AUC suggests that IgG Fc
targeting was responsible for an 11.5-fold increase in NP absorption.
Oral Delivery of Insulin to Wild-type Mice
NP-Fc that are capable of encapsulating insulin were developed as a model NP-based
therapeutic for diabetes that could be orally administered and evaluated for eliciting a
pharmacologic response. Insulin NPs (insNP) were prepared using nanoprecipitation after
dissolving insulin and PLA-PEG-MAL in dimethyl sulfoxide (DMSO), resulting in an
insulin load of 0.5% (w/w). The nanoprecipitation method allowed the particle size to
remain small (mean hydrodynamic diameter, 57 nm) while still allowing insulin
encapsulation. The release of insulin from insNP in PBS at 37°C demonstrated a strong
burst release in the first hour followed by a controlled release (Fig. 5A). The insulin release
profile was advantageous because it allowed all of the insulin to be delivered before
complete clearance of the particles after 10 h. To determine the bioactivity, insulin released
from insNP was collected and injected into fasted wild-type mice by tail-vein injection. The
bioactivity was measured by monitoring the blood glucose and comparing the response to an
equivalent dose of free insulin solution (3.3 U/kg). The released insulin generated a
hypoglycemic response in mice (Fig. 5B), indicating that the encapsulated insulin was
bioactive after release from the insNP.
The hypoglycemic response generated after oral administration of the targeted insNP
(insNP-Fc) was tested using fasted wild-type mice and compared with the efficacies of non-
targeted insNP, free insulin, and NP-Fc without insulin (Fig. 5C). The free insulin
administered orally did not generate a glucose response in the mice, unlike the free insulin
injected into the tail vein that was able to generate a glucose response (Fig. 4B). The NP-Fc
without insulin also was unable to generate a glucose response. The glucose response
generated by non-targeted insNP was not different from that generated by the control groups
at any time point. However, insNP-Fc caused a significant hypoglycemic response in the
mice, reducing the glucose during the first 10 h after administration. This is consistent with
the biodistribution (Fig. 4A) and insulin release data (Fig. 5A), which demonstrated that the
particles were cleared and the insulin was released within 10 h, respectively. The blood
glucose level then increased and was similar to that of the control groups by 15 h. The
insNP-Fc insulin dose required to generate the hypoglycemic response was 1.1 U/kg, which
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is clinically relevant (28) and lower than other oral insulin delivery systems that require 10–
100 U/kg to generate a glucose response (29). When compared with the glucose response
from free insulin administered by tail vein injection (Fig. 5B), the orally administered
insNP-Fc resulted in a prolonged (15 h vs. 1.5 h) hypoglycemic response (Fig. 5C).
To demonstrate that the enhanced hypoglycemic response generated by insNP-Fc was due
specifically to the IgG Fc ligand on the NP surface, several additional control groups were
tested. The first control was to administer insNP-Fc concurrently with a 50-fold excess of
free IgG Fc. The second control was to conjugate chicken IgY Fc fragments to insNP
instead of human IgG Fc fragments. [Chicken IgY is the functional equivalent of IgG in
non-mammalian species such as birds, but does not bind to mouse FcRn (30).] Both control
groups had hypoglycemic responses that were significantly less than insNP-Fc (Fig. 5D),
indicating that the use of the IgG Fc as a targeting ligand was responsible for the enhanced
hypoglycemic response.
Oral Delivery of Insulin to FcRn Knockout Mice
The role of FcRn in NP transepithelial transport was tested by repeating the efficacy
experiment using FcRn knockout (KO) mice. FcRn KO mice had the same insulin
sensitivity as the wild-type mice, so the same insulin dose was used for both strains (Fig.
5E). In contrast to the results in the wild-type mice (Fig. 5C), insNP-Fc did not generate a
hypoglycemic response significantly different from the other three groups in the FcRn KO
mice (Fig. 5F). In these FcRn KO mice, the response generated by insNP-Fc resembled the
response generated by non-targeted insNP in the wild-type mice (Fig. 5C), suggesting that
the benefit gained from using Fc was specifically due to FcRn.
In vivo Glucose Response Dose-Dependency
The glucose response in both wild-type and FcRn KO mice was evaluated for dose
dependency using two different doses of insNP-Fc: 0.66 U/kg and 1.1 U/kg (Fig. 5G). For
the FcRn KO mice, there was no difference in the glucose response between the two doses
of insNP-Fc. However, for the wild-type mice, the glucose response was significantly
greater at the higher dose of insNP-Fc, suggesting a possible dose-dependence in the wild-
type mice.
Discussion
For many diseases, oral administration of therapeutics is the standard of care because daily
therapy is required. In some cases, chronic diseases, such as cancer, that have been treated in
the clinic with intravenous infusions are now increasingly being treated with oral
therapeutics because patients prefer the convenience of oral administration relative to
parenteral administration. For NP-based therapeutics to be a practical treatment of many
diseases, NP formulations appropriate for oral administration are necessary. The most
significant barrier to the effective oral administration of NPs is the intestinal epithelium,
which limits the absorption of NPs. To date, there is no practical solution to this problem.
There have been many attempts to develop oral drug delivery systems that overcome this
barrier (29). For example, permeation enhancers have been used to open tight junctions to
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allow both paracellular and transcellular transport of drugs across the epithelium (31).
Mucoadhesive biomaterials have been used to increase the retention time and local
concentration of drugs near the apical surface of epithelial cells (32). Many oral NPs have
been engineered for uptake by M cells in the Peyer’s Patches, although this limits the
surface area available for absorption and exposes NPs to underlying immune cells (33).
Finally, a few NP formulations have targeted cell receptors, but they still suffer from low
bioavailability and require high oral drug dosages (29, 34).
We have taken a novel approach to address this problem by developing drug encapsulated
NPs capable of targeting FcRn for transepithelial transport and enhanced NP intestinal
absorption after oral administration. FcRn has been shown to mediate the transcytosis of IgG
across several epithelial and endothelial barriers (11), and more recently the transcytosis of
fluorescent NPs was demonstrated across a monolayer of Calu-3 airway epithelial cells in
vitro after adsorption of Fc on the NP surface (22). Harnessing the transcytosis pathway to
cross the intestinal epithelium offers the advantage of leaving intact the integrity of the
epithelial barrier, avoiding potential safety issues and adverse effects associated with
manipulating the permeability of the intestine for paracellular or transcellular transport. An
additional advantage of targeting the FcRn is that this receptor is expressed throughout the
intestine, providing a significant increase in the available absorption surface area for NP-Fc,
which is in contrast with other drug delivery systems that target only a specific portion of
the intestine such as the Peyer’s patches (6).
We have demonstrated that targeting FcRn for transepithelial transport by modifying the NP
surface with IgG Fc provides a successful approach for the oral delivery of NPs. Using a
mouse model, we demonstrated that FcRn enabled the NP-Fc to cross the intestinal
epithelium and reach systemic circulation. The use of IgG Fc to target the NPs to FcRn
resulted in absorption efficiency 11.5-fold higher than for nontargeted NPs, but the
efficiency could potentially be higher, as some 14C could have been absorbed in other
tissues not measured in these studies. Furthermore, insNPs targeting FcRn, a model NP-
based therapeutic for the treatment of diabetes, were able to generate a hypoglycemic
response after oral administration at a clinically relevant insulin dose that is significantly
lower than the doses required by other drug delivery systems designed for oral insulin
delivery (29). Moreover, rodents significantly downregulate the FcRn expression in the
intestine after weaning (35), but humans continue to express FcRn into adulthood.
Therefore, while NP-Fc can increase transepithelial transport in mice, the transport in
humans could potentially be even more efficient.
There are some potential limitations to this technology that need to be investigated. For
example, FcRn is expressed in many tissues in addition to the intestine. Using IgG Fc to
target the FcRn could potentially result in uptake in tissues other than the targeted tissue.
However, FcRn expression in tissues such as the vascular endothelium, blood-brain barrier,
and lungs could also allow the technology to be expanded for drug delivery across other
cellular barriers. Immunological responses to Fc on the NP surface need to be investigated
as well. The presence of IgG Fc may result in faster blood clearance of the NPs due to
interactions with Fc receptors. NP-Fc may also generate immunological responses and thus
could potentially be used for oral vaccine applications (36).
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This technology may have a major impact on the treatment of several diseases by enabling
NP-based therapies to be orally administered. In addition, the encapsulation of drugs or
biologics that are currently limited by low bioavailability into NPs that target FcRn may
enable markedly more efficient oral delivery of the therapies. The path forward for
translation of this technology to the clinic is to test the NP-Fc in larger animal models such
as pigs and non-human primates. Some key parameters that need to be understood for
success in the clinic are the ideal release profile for an oral insulin formulation and how
absorption varies based on diet and patient-to-patient variability.
Materials and Methods
Synthesis of Polymers
D,L-Lactide (Sigma-Aldrich) and MAL-PEG-OH (JenKem Technology) were used to
synthesize PLA-PEG-MAL by ring opening polymerization. D,L-Lactide (3 g, 20.8 mmol)
and MAL-PEG-OH (544 mg, 0.16 mmol) were dissolved in 15 mL anhydrous toluene in a
round bottom flask. Tin(II) ethylhexanoate (38 mg, 0.09 mmol) was then added. The flask
with condenser was placed in an oil bath, purged with nitrogen for 10 minutes, heated to
120°C, and reacted overnight while 4°C water circulated through the condenser. Toluene
was then evaporated and the polymer precipitated in a 50:50 (v/v) mixture of ice-cold
methanol and diethyl ether and vacuum-dried. The PLA-PEG-MAL was characterized by 1H
NMR (400 MHz), δ = 5.28–5.11 (br, -OC-CH(CH3)O- in PLA), 3.62 (s, -CH2CH2O- in
PEG), 1.57–1.45 (br, -OC-CHCH3O- in PLA). Using GPC, the polymer Mn = 12.5 kDa with
Mw/Mn = 1.47 relative to polystyrene standards. Poly(lactic acid) (PLA) (inherent viscosity
0.50 dL/g) with terminal carboxylate groups (Lactel) was conjugated to 14C doxorubicin
(Perkin Elmer) (PLA-14C) and Alexa Fluor 647 (AF647) hydrazide tris(triethylammonium)
salt (Invitrogen) (PLA-AF647) were prepared the same way. PLA (30 mg, 0.83 μmol) in 1
mL dimethylformamide (DMF) was reacted with N-hydroxysuccinimide (NHS) (0.5 mg, 4.2
μmol) in the presence of 1-ethyl-3-[3-dimethylaminopropyl] (0.8 mg, 4.2 μmol) overnight.
PLA-NHS was precipitated in a 50:50 (v/v) mixture of ice-cold methanol and diethyl ether
and vacuum-dried. For PLA-14C, PLA-NHS (18 mg, 0.5 μmol) was mixed overnight
with 14C Doxorubicin (0.27 mg, 0.5 μmol) in 1 mL DMF. For PLA-AF647, PLA-NHS (50
mg, 1.4 μmol) was mixed overnight with Alexa Fluor 647 (1.5 mg, 1.4 μmol) in 1 mL DMF.
Both polymers were precipitated in a mixture of 50:50 (v/v) ice-cold methanol and diethyl
ether and vacuum-dried.
Synthesis and characterization of NP-Fc
To prepare the NP-Fc, 3 mg PLA-PEG-MAL was dissolved in 300 μL acetonitrile and added
dropwise to 1.5 mL water. The solution was mixed for 2 h, and the NPs were purified by
filtration using Millipore Amicon Ultra 100,000 NMWL. The NPs were washed 2x with
water and 2x with phosphate-buffered saline (PBS) containing 5 mM EDTA. Concurrently,
86 μg of purified human polyclonal IgG Fc prepared by papain digestion (Bethyl
Laboratories) or 95 μg of chicken IgY Fc (Jackson ImmunoResearch Laboratories) in PBS
containing 5 mM EDTA was reacted with 0.48 μL of 5 mg/mL 2-iminothiolane (Traut’s
Reagent) for 1 h. The modified Fc was added to the NPs and mixed for 1 h to allow
conjugation at 4°C. The NP-Fc were washed with PBS using Millipore Amicon Ultra
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100,000 NMWL. The conjugation of IgG Fc to the NP surface was measured using a protein
bicinchoninic acid (BCA) assay from Lamda Biotech. Particle diameter and surface charge
(zeta potential) were measured using dynamic light scattering with a Brookhaven
Instruments ZetaPALS.
In vitro Transcytosis Studies
Transepithelial transport studies utilized Transwell plates (Costar) with a Caco-2 (American
Type Culture Collection - ATCC) cell density of 5.5 ×104 in media [ATCC formulated
Eagle’s Minimum Essential Medium with aqueous penicillin G (100 units/mL),
streptomycin (100 U/mL), and fetal bovine serum (FBS, 20%)]. On the day of the transport
experiment, the media was changed to HBSS pH 6.5 in the apical chamber and HBSS pH
7.4 in the basolateral chamber and allowed to equilibrate for 1 h at 37°C and 5% CO2. Prior
to the experiment and at the end of the experiment, the monolayer integrity was checked by
measuring the transepithelial resistance (TEER) using a Millicell-ERS (Millipore). TEER
values were 900–1000 Ω/cm2 for wells used in transport experiments and the TEER
remained constant throughout the experiments. 3H-labeled NPs were prepared by blending
50 μg 3H-poly(lactic-co-glycolic acid) (PLGA) (Perkin Elmer) with 1 mg PLA-PEG-MAL
in 100 μL acetonitrile prior to nanoprecipitation in 500 μL water and then washed in HBSS
pH 6.5 prior to the transport experiment. The apical solution was then replaced with a
solution of 100 μg 3H-labeled NPs or NP-Fc in 250 μL HBSS pH 6.5. The NP formulations
were incubated for 24 h before measuring the 3H content in the basolateral chamber. The
basolateral solution was collected and added to a Hionic-Fluor scintillation cocktail (Perkin
Elmer) before analysis using a Packard Tri-Carb Scintillation Analyser. At the end of the
experiment, the TEER was measured again to verify monolayer integrity. For the IgG Fc
blocking experiment, a 50x molar excess of IgG Fc relative to Fc on the NP-Fc surface was
added concurrently with NP-Fc to the apical chamber, and the 3H content in the basolateral
chamber was measured after 24 h.
Western Blot
Sections of small intestine and colon were removed from wild-type mice after euthanasia.
Intestinal epithelial cells were isolated (37, 38) and the protein was extracted. Protein
concentrations in the extracts were determined using the BCA assay. Extracts were resolved
on a 12% SDS-PAGE gel under reducing conditions. Proteins were transferred onto a
nitrocellulose membrane. The membrane was blocked with 5% nonfat milk, probed with
rabbit anti-mouse FcRn (Santa Cruz Biotech) for 1 h, and then incubated with goat anti-
rabbit IgG-HRP (Santa Cruz Biotech). All blocking, incubations, and washes used PBS-T
(PBS with 0.05% Tween 20). Detection was by chemiluminescence. Band intensity was
quantified using ImageJ.
Immunohistochemistry
Small intestine tissues were harvested and fixed in 10% formalin overnight. After ethanol
dehydration, tissues were paraffin embedded and cut into 8 μm-thick sections, mounted on
slides, and dried overnight. The tissues were then rehydrated using xylene and ethanol.
Endogenous peroxidase activity, endogenous biotin, and nonspecific proteins were blocked
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with 3% H2O2, avidin blocking agent, and 10% goat serum, respectively. The samples were
incubated with polyclonal rabbit IgG or anti-mouse FcRn IgG (Santa Cruz Biotech) primary
antibody overnight, then incubated with biotinylated anti-rabbit secondary antibodies (Santa
Cruz Biotech), with streptavidin-HRP, developed with DAP, and mounted with hematoxylin
counterstain.
In vivo Fluorescence Imaging
All animal studies were conducted under the supervision of MIT’s Division of Comparative
Medicine in compliance with the NIH’s Principles of Laboratory Animal Care. Wild-type
Balb/c mice (Charles River Laboratories) (n=3) were fasted overnight prior to gavage.
Fluorescently-labeled NPs were prepared by blending 100 μg PLA-AF647 with 1 mg PLA-
PEG-MAL in 100 μL acetonitrile prior to nanoprecipitation in 500 μL water. Fluorescently-
labeled NP and NP-Fc were washed 3x in water until the flow-through was clear and
suspended in 200 μL water (7 mL water/kg). The suspension was then administered to the
mice by oral gavage. After 1.5 h, the mice were euthanized. Duodenum tissue sections were,
frozen into Tissue-Tek OCT using liquid nitrogen. Cross sections of the tissue were obtained
using a Leica CM1900 Cryostat with a thickness of 12 μm. The tissue was air-dried
overnight and then stained with Prolong Gold (Life Technologies) antifade reagent with 4′,
6-diamidino-2-phenylindole (DAPI). Fluorescent images were obtained using a Zeiss LSM
710 NLO scanning confocal microscope under oil immersion at 40x magnification.
In vivo Biodistribution
To prepare 14C-labeled NPs, 450 μg PLA-14C was blended with 3 mg PLA-PEG-MAL in
300 μL acetonitrile prior to nanoprecipitation in 1.5 mL water. NPs were washed 2x with
water and 2x with PBS. 14C release was measured by preparing a batch of 14C NPs in PBS
with pH 7.4 and dividing the batch equally into 500 μg samples for incubation at 37°C. At
each timepoint, samples were collected, washed 3x with PBS using Millipore Amicon Ultra
100,000 NMWL, and then added to 15 mL of Hionic Fluor scintillation cocktail. The
activity was counted using a Packard Tri-Carb Scintillation Analyser. For the in vivo
biodistribution experiments, 6–12 week old wild-type mice were fasted 8 h prior to oral
gavage of 1.5 mg (0.1 μCi/mouse) of 14C-labeled NP and NP-Fc in 7 mL PBS/kg. Groups of
mice (n=5 mice) were euthanized at each time point, and the spleen, kidneys, liver, lungs,
and heart were harvested. Each organ was placed directly in a scintillation vial except for the
liver, which was homogenized and ~100 mg was analyzed. Each organ was solubilized in 2
mL of Solvable (Perkin Elmer) for 12 h at 60°C and then decolored with 200 μL of 0.5 M
EDTA (Invitrogen) and 200 μL 30% hydrogen peroxide (Fisher Scientific) for 1 h at 60°C.
The activity was counted in 15 mL Hionic-Fluor scintillation cocktail using a Packard Tri-
Carb Scintillation Analyser. To determine 100% dose, vials of 500 μg NPs and NP-Fc were
counted in 15 mL Hionic-Fluor scintillation cocktail. For the oral absorption efficiency,
total 14C counted in all tissues was added at each time point. The AUC of total absorbed 14C
versus time was calculated using the trapezoid method and divided by the initial dose to
determine the oral absorption efficiency. The results were reported as mean ± SEM, and
comparison of non-targeted NPs and NP-Fc utilized the two-tailed Student’s t-test.
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Insulin Encapsulation and Release
Insulin NPs were prepared by blending 900 μg human recombinant insulin (Sigma-Aldrich),
450 μg PLGA (50:50 G:L, inherent viscosity 0.20 dL/g) with terminal carboxylate groups
(Lactel), and 3 mg PLA-PEG-MAL together in 525 μL dimethyl sulfoxide (DMSO) prior to
nanoprecipitation in 2.1 mL water. Free insulin was removed using Millipore Amicon Ultra
100,000 NMWL by washing 2x with water and 2x with PBS. Insulin encapsulation was
measured by heating the NPs to 60°C for 30 min, and insulin was quantified using a BCA
assay or insulin ELISA kit (Millipore). Insulin release from the NP was measured by
dividing a batch of insNP equally into 24 kDa dialysis units (Pierce) and incubating at 37°C
in PBS with pH 7.4. At each timepoint, three samples of insNP were collected, washed with
PBS using Millipore Amicon Ultra 100,000 NMWL, heated to 60°C for 30 min, and
measured for insulin using a BCA assay.
Insulin Activity
Insulin activity was measured by preparing insNP and allowing insulin release for 2 h at
37°C in PBS at pH 7.4. Wild-type mice were fasted for 8 h, and the mice (n=3/group) used
were chosen so that the mean initial blood glucose levels were the same for each group. 3.3
U/kg of released insulin was administered to the fasted mice by tail-vein injection. An
equivalent dose of free insulin by mass was administered by tail-vein injection to another
group of fasted mice. The blood glucose level was measured using the Contour blood
glucose monitor (Bayer).
In vivo Efficacy
6–12-week old wild-type or FcRn knockout (39) mice (Jackson Laboratories) were fasted
for 8 hours. Mice (n=5–6) were chosen per group such that the mean initial blood glucose
levels were the same per group. 150 or 250 μg of insNP or insNP-Fc (insulin dose −0.66 or
1.1 U/kg) in 7 mL PBS/kg were administered to the mice by oral gavage. For controls, 1.1
U/kg of free insulin and 250 μg of NP-Fc without insulin in 7 mL PBS/kg were administered
by oral gavage. For the excess IgG Fc control, 250 μg of insNP-Fc was formulated with 50x
molar excess of IgG Fc in 7 mL PBS/kg prior to administration to the mice by oral gavage
The blood glucose level was measured as described above.
Statistical Analysis
All data are presented as means with either SD or SEM as indicated. Statistical significance
was determined by a two-tailed Student’s t test (α= 0.05) assuming equal variance.
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Fig. 1. Schematic of Fc-targeted nanoparticle transport across the intestinal epithelium by the
FcRn through a transcytosis pathway
(1) IgG Fc on the NP surface binds to the FcRn on the apical side of absorptive epithelial
cells under acidic conditions in the intestine. (2) NP-Fc are then trafficked across the
epithelial cell through the FcRn transcytosis pathway in acidic endosomes. (3) Upon
exocytosis on the basolateral side of the cell, the physiological pH causes IgG Fc to
dissociate from the FcRn, and NP-Fc are free to diffuse through the intestinal lamina propria
to the capillaries or lacteal and enter systemic circulation.
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Fig. 2. Nanoparticle assembly, characterization, and in vitro transepithelial transport
(A) Schematic of NP-Fc assembly. NPs consist of a biodegradable PLA core for drug
encapsulation and a PEG surface coating for particle stability and to reduce phagocytic
uptake. NPs were formed using the nanoprecipitation self-assembly method (25) and
surface-modified with IgG Fc for FcRn targeting. (B) Dynamic light scattering
measurements for non-targeted NPs and NP-Fc. Data are means ± SD (n=3). (C) IgG Fc
ligand density on the NP surface with (Fc-SH) and without (Fc) thiol modification of the
IgG Fc. Data are means ± SD (n=3). (D) In vitro transepithelial transport of non-targeted
NPs, NP-Fc, and NP-Fc with an excess of human IgG Fc as a blocking agent for FcRn. Data
are expressed as mean basolateral 3H disintegrations per minute (DPM) as a percentage of
the initial amount of 3H (± SEM; n = 4 wells per group). *P < 0.05, two-tailed Student’s t-
test.
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Fig. 3. FcRn expression and nanoparticle intestinal uptake in mice
(A) Western blot of mouse FcRn (mFcRn) in mouse intestinal tissue. (B) Quantification of
Western blot band intensity. The relative band intensity was calculated as the ratio of
mFcRn to B-Actin band intensity from the Western Blot. (C) Immunohistochemistry on
sections of mouse duodenum. mFcRn appears brown. The negative control was tissue
stained with polyclonal IgG. (D) Fluorescently labeled NPs (red) were administered to
fasted wild-type mice by oral gavage and the intestines were collected for sectioning and
imaging 1.5 h after administration. The panels are confocal fluorescence images of 12-μm
sections of mouse duodenum. Cell nuclei were stained with DAPI (blue). Images are
representative for n=3 mice.
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Fig. 4. Nanoparticle absorption and biodistribution in mice
(A) Biodistribution of 14C-labeled non-targeted NPs and NP-Fc after oral administration to
fasted wild-type mice. Data are mean % initial dose (ID) per gram of tissue ± SEM (n=5
mice per time point). (B) Release of 14C from 14C-labeled NPs in PBS at 37°C. Data are
means ± SD for n=4 release experiments. (C) Total absorbed 14C over time for non-targeted
NPs and NP-Fc after administration by oral gavage. Data are mean %ID measured in all of
the organs added together ± SEM (n=5 mice per time point). **P < 0.01 for comparison of
non-targeted NPs and NP-Fc at respective time point, two-tailed Student’s t-test.
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Fig. 5. Encapsulation of insulin and oral delivery of Fc-targeted insulin nanoparticles to mice
(A) Release of insulin from insNP into PBS. Data are means ± SD (n=3 per time point). (B)
Blood glucose response of fasted wild-type mice to insulin encapsulated and released from
NPs in (A) before administration. Fasted wild-type mice received free insulin (3.3 U/kg)
administered by tail-vein injection. Data are means ± SEM (n=3 mice per group). (C) Blood
glucose response of fasted wild-type mice to free insulin solution, NP-Fc containing no
insulin, non-targeted insNP, and insNP-Fc, each administered by oral gavage. Data are
means ± SEM (n=6 mice per group). *P < 0.05 for comparison of non-targeted insNP and
insNP-Fc at corresponding time points, two-tailed Student’s t-test. (D) Blood glucose
response of fasted wild-type mice to insNP-Fc, insNP-Fc administered concurrently with
excess of IgG Fc, and insNP with chicken IgY Fc fragments, each administered by oral
gavage. Data are means ± SEM (n=5 mice per group). **P<0.01 for comparison between
insNP-Fc with insNP-Fc + free IgG Fc at the 15 and 19 h timepoints and between insNP-
IgG Fc and insNP-IgY Fc at the 10, 15, and 19 h timepoints using a two-tailed Student’s t-
test. (E) Blood glucose response to equivalent insulin doses (3.3 U/kg) administered by tail-
vein injection into fasted wild-type and FcRn KO mice. Data are means ± SEM (n=3 mice
per group). (F) Fasted FcRn KO mice blood glucose response to free insulin solution, NP-Fc
containing no insulin, non-targeted insNP, or insNP-Fc, each administered by oral gavage.
Data are means ± SEM (n=5 mice per group). (G) Fasted wild-type and FcRn KO mice were
dosed by oral gavage with non-targeted insNP and insNP-Fc at two different doses. *P<0.05
for comparison between insNP-Fc at 1.1 U/kg and each of the other groups at corresponding
timepoints, two-tailed Student’s t-test.
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